IMA (ImageneBio) Research & Development: $24.79 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMA ImageneBio Inc IMA
10 GF Score
Price $5.60
! 3 Warning Signs
View Full Analysis

What is ImageneBio Research & Development?

ImageneBio IMA +0.18% 10 Research & Development is $24.79 Mil as of Mar. 2026. GuruFocus rates IMA with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ImageneBio's Research & Development for the three months ended in Mar. 2026 was $5.96 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $24.79 Mil.

ImageneBio  (NAS:IMA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ImageneBio Research & Development Related Terms

ImageneBio Research & Development Historical Data

* Premium members only.

The historical data trend for ImageneBio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImageneBio Research & Development Chart

ImageneBio Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
21.93 32.11 28.53

ImageneBio Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial 3.76 4.04 15.56 3.27 5.96
IMA
10GF Score
ImageneBio Inc IMA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImageneBio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $24.79 Mil mean?
ImageneBio (IMA) has a Research & Development of $24.79 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ImageneBio and its competitors.
Is ImageneBio's Research & Development too high?
ImageneBio's current Research & Development is $24.79 Mil. Overall, ImageneBio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ImageneBio's Research & Development compare to HYFT and CING?
ImageneBio's Research & Development of $24.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ImageneBio and its competitors. ImageneBio's current Research & Development is $24.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImageneBio stock overvalued right now?
ImageneBio (IMA) has a current Research & Development of $24.79 Mil. The current Research & Development is $24.79 Mil. ImageneBio's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ImageneBio (IMA), the current Research & Development is $24.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImageneBio Business Description

Address 12526 High Bluff Drive, Suite 345, San Diego, CA, USA, 92130
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
10GF Score

Get the complete analysis for IMA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.60
Price